(19)
(11) EP 1 090 133 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.11.2009 Bulletin 2009/48

(45) Mention of the grant of the patent:
12.08.2009 Bulletin 2009/33

(21) Application number: 99926204.1

(22) Date of filing: 21.06.1999
(51) International Patent Classification (IPC): 
C12N 15/82(2006.01)
A61K 38/17(2006.01)
 C12N 15/12(2006.01)
(86) International application number:
PCT/CA1999/000577
(87) International publication number:
WO 1999/067401 (29.12.1999 Gazette 1999/52)

(54)

PRODUCTION OF IL-10 IN NON-FOOD CROP PLANT BIOREACTOR

HERSTELLUNG VON IL-10 IN EINEN PFLANZENBIOREAKTOR AUS PFLANZEN, DIE NICHT ZUR ERNÄHRUNG VERWENDET WERDEN

PRODUCTION DE IL-10 DANS UN BIOREACTEUR DE PLANTES CULTIVEES NON ALIMENTAIRES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 22.06.1998 US 102050

(43) Date of publication of application:
11.04.2001 Bulletin 2001/15

(73) Proprietors:
  • HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Agriculture and Agri-Food
    Ontario N5V 4T3 (CA)
  • Queen's University
    Kingston, Ontario K7L 3N6 (CA)
  • The John P. Robarts Research Institute
    London, Ontario N6A 5K8 (CA)
  • London Health Sciences Center
    London, Ontario, N6A 4G5 (CA)

(72) Inventors:
  • BRANDLE, Jim
    London, Ontario N6A 3Y5 (CA)
  • DAVIES, Peter, L.
    Kingston, Ontario K7M 2M8 (CA)
  • KENWARD, Kimberley, D.
    London, Ontario N6A 1M1 (CA)
  • MENASSA, Rima
    London, Ontario N5X 1W4 (CA)
  • JEVNIKAR, Tony
    London, Ontario N6H 3Y8 (CA)
  • DELOVITCH, Terry
    London, Ontario N6G 2S6 (CA)

(74) Representative: Main, Malcolm Charles et al
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)


(56) References cited: : 
WO-A-93/03161
 CA-A- 2 188 220
   
  • SPURGEON D.: "Tobacco could be used to produce interleukin 10" BRITISH MEDICAL JOURNAL, vol. 319, no. 7203, 17 July 1999 (1999-07-17), pages 143-143, XP002127522
  • LEVINE ET AL.: "High level expression and refolding of mouse interleukin 4 synthesized in E. coli." J. BIOL. CHEM., vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7445-7452,
  • SYTO ET AL.: "Structural and biological stability of the human interleukin 10 homodimer" BIOCHEMISTRY, vol. 37, 11 July 1998 (1998-07-11), pages 16943-16951,
  • VIEIRA ET AL.: "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI" PNAS, vol. 88, February 1991 (1991-02), pages 1172-1176,
  • ZDAVOV ET AL.: "Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma" CURRENT BIOLOGY-STRUCTURE, vol. 3, 15 June 1995 (1995-06-15), pages 591-601,
  • WERNER ET AL.: "Appropriate mammalian expression systems for biopharmaceuticals" ARZNEIM. -FORSCH./DRUG RES., vol. 48, no. II-8, 1998, pages 870-880,
  • EDELBAUM ET AL.: "Expression of active human interferon-beta in transgenic plants" J. INTERFERON RES., vol. 12, 1992, pages 449-453,
  • MENASSA ET AL.: "Therapeutic effectiveness of orally administered transgenic low-alkaloid tobacco expressing human interleukin-10 in a mouse model of colitis" PLANT BIOTECHNOLOGY JOURNAL, vol. 5, 2006, pages 50-59,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).